Kornimate/medical-research-clean huggingface dataset:
remote ischemic conditioning for efficacy in patients with aneurysmal subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage; Cerebrovascular Disorders; Brain Diseases; Stroke; Cardiovascular Diseases; Vascular Diseases; Nervous System Diseases

Summary: several recent large-scale clinical trials aimed at improving subarachnoid hemorrhage(sah) outcomes have concluded with negative results, failing to enhance the prognosis for these patients. consequently, there is an urgent demand for novel treatment strategies and approaches to address the challenges posed by sah. remote ischemic conditioning(ric) has gained considerable attention in the treatment of stroke, particularly ischemic stroke, with numerous studies demonstrating its potential to enhance neurological outcomes compared to conventional treatments alone.ric for the treatment of sah is an investigative strategy in its initial stages. the neuroprotective effects of ric, particularly its potential to preserve cranial nerve function and ameliorate neurological deficits, confer significant value in the treatment of sah patients. the precise manner in which sah patients may benefit from ric treatment, and the mechanisms by which it improves neurological function, remain to be fully understood. consequently, randomized controlled trials are necessary to validate the efficacy of ric in this patient population and to delineate the optimal therapeutic protocols for its application. based on the above discussion, this study aims to explore the efficacy and safety of ric in the treatment of sah.


Eligibility criteria:
inclusion criteria: 1. patients with aneurysmal subarachnoid hemorrhage confirmed by imaging examination (diagnosed by computed tomography and confirmation of an intracranial aneurysm by ct angiography or digital subtraction angiography); 2. the hunt-hess grade is 2-3 at admission; 3. onset of aneurysmal subarachnoid hemorrhage ≤72 hours; 4. the responsible aneurysm has been treated by endovascular interventional therapy; 5. 18≤ age ≤80 years old; 6. informed consent must be obtained from participants or legally authorized representatives. exclusion criteria: 1. patients with other intracerebral hemorrhage or other types of subarachnoid hemorrhage; 2. previous neurological deficits (mrs score ≥1) or psychiatric disorders that can confound neurological or functional assessments; 3. with severe comorbidities and a life expectancy of less than 90 days; 4. refractory hypertension (systolic blood pressure\> 180 mmhg or diastolic blood pressure \>110 mmhg); 5. contraindications of ric: severe soft tissue injury of the lower limbs, etc; 6. concurrent participation in another protocol investigating a different experimental therapy; 7. any condition that the investigator believes may increase the patient's risk.
comparation of bilateral and unilateral erector spinae plane block

Conditions: Postoperative Pain, Acute; Regional Anesthesia; Multimodal Analgesia

Summary: although laparoscopic cholecystectomy is a minimally invasive surgery with many advantages, it is one of the operations with high postoperative pain scores. opioids are frequently used to prevent postoperative pain. due to the side effects of opioids, the amount of use is tried to be reduced. regional anesthesia techniques can be used to minimize opioid consumption. erector spina plane block was first described in 2016 by forero et al. in the treatment of thoracic neuropathic pain. since then, esp block has been used as an anesthetic and analgesic technique. it is applied by injecting local anesthetic into the fascial plane located between the erector spina muscle and the transverse process of the vertebra. several high-level studies have shown that the esp block can be used to reduce postoperative pain after gastrointestinal surgery. several studies have evaluated the effect of esp block for pain relief after laparoscopic cholecystectomy. esp block has been applied unilaterally or bilaterally in various studies. however, in the current studies in the literature, the advantages or disadvantages of the bilateral application of the esp block compared to the unilateral application have not been evaluated. in this study, the investigators aimed to evaluate postoperative pain by applying esp block to patients who underwent laparoscopic cholecystectomy and to evaluate the advantages of unilateral or bilateral application of esp block over each other.


Eligibility criteria:
inclusion criteria: * patients who underwent laparoscopic cholecystectomy surgery between december 2021 and january 2022 will participate in the study. exclusion criteria: * there is no exclusion criteria for the study.

Keywords: esp block
seat cushions adaptations on upper extremity function in cerebral palsy children

Conditions: Cerebral Palsy

Summary: as the seating adaptations, ranging from simple to complex, standard and customized may facilitate optimal health and maximize functional participation despite limited postural control; the study will be conducted for determine the effect of contoured cushions as a seat adaptation on upper extremity function in children with spastic cerebral palsy and compare between the effect of flat cushion and contoured cushion in adaptive seating system on upper extremity function in children with spastic cerebral palsy.

as research continues to reveal the efficacy of ramped and contoured cushions on postural stability and alignment (macdonald et al.,2015), it is likely that it will become accepted that such modifications will affect the ul functional level , mobility and rang of motion. therefore, the purpose of this study was to examine the effect of contoured cushions as adaptive seating intervention on upper extremity function in children with spastic cerebral palsy.

Eligibility criteria:
inclusion criteria: 1. their age ranged from three to six years old . 2. spasticity ranged from 1+ to 2 grade according to modified ashwarth scale . 3. all children should be able to sit on the adaptive seat while head is upright independently and hands are free; preliminary test by gross motor functional measurement (gmfm) scale ranged score from ( 21 to 25 ) in sitting domain. exclusion criteria: any child with the following criteria will be directly excluded from the evaluation for the consistency of the sample and statistically obtained results: 1. visual and/or auditory defects which interfere with upper extremity functions. 2. fixed deformity of one or both upper limbs which limit passive rom in shoulder and elbow. 3. children with mixed type, dyskinetic or ataxic cerebral palsy are excluded. 4. surgical intervention in both upper limbs or botulinum toxin injection in the last 6 months before the time of assessment . 5. any recent trauma of one or both upper limbs.

Keywords: seat cushions, upper extremity , cerebral palsy
evaluation of everon™ - a contact-free system for measuring heart rate, respiratory rate and motion

Conditions: Post Surgical Pat., Medical Pat., Resp. Failure, Car.Arrest, Death

Summary: evaluation of continuous monitoring device on patients risk during hospitalization and nurse satisfaction level.

to assess the effects of continuous patient monitoring using a contactless monitor in a medical-surgical unit on transfers and length of stay at higher level of care units

Eligibility criteria:
inclusion criteria: * hospitalized patients exclusion criteria: * none

Keywords: all hospitalized patients in a general med/ surg unit
pain relief after trapeziectomy: ibuprofen & acetaminophen versus oxycodone

Conditions: Pain, Postoperative; Osteoarthritis Thumb

Summary: in the us, pain management after surgery for surgical treatment of osteoarthritis at the base of the thumb typically consists of prescription opioids during the early recovery phase. given the highly addictive nature of prescription opioids, guidelines are being evaluated by hand surgeons to reduce opioid use while still maintaining pain control after surgery. a promising approach is to use non-narcotic medication as the first line of treatment. the purpose of this study is to demonstrate the efficacy of a combination of non-steroidal anti-inflammatory drugs (nsaids), ibuprofen and acetaminophen, in comparison to a morphine analogue substance (oxycodone) for pain management in the first 30 days after surgery.


Eligibility criteria:
inclusion criteria: * undergoing trapeziectomy for thumb osteoarthritis english proficient, exclusion criteria: * pregnancy current use of opioids concurrent surgeries (ex. trapeziectomy combined with carpal tunnel release) inability to complete study forms (education, cognitive ability, mental status, medical status) allergy or intolerance to ibuprofen, acetaminophen and/or oxycodone liver or kidney dysfunction, abnormal liver enzymes restricting use of acetaminophen or ibuprofen history of chronic heart failure, upper gastrointestinal bleeding or coagulopathy history of complex regional pain syndrome
real world european investigation of safety and clinical efficacy of the evoque system (triscend iii eu)

Conditions: Tricuspid Valve Regurgitation; Heart Valve Diseases; Cardiovascular Diseases

Summary: this is a prospective, single-arm, multi-center, real-world study of an the edwards evoque system.

this is a prospective, single-arm, multi-center, real-world study of an approved device. up to 500 patients will be enrolled in this study at up to 45 sites in europe. all enrolled patients will be assessed at the following intervals: baseline, index procedure, discharge (or 7-days post-index procedure whichever occurs first), 30 days, 1 year, and annually through 5 years. study enrollment is expected to last approximately 2-4 years, followed by 5 years of follow-up.

Eligibility criteria:
inclusion criteria: 1. the local site heart team determines that the patient is appropriate for transcatheter tricuspid valve replacement with the evoque system per the current instructions for use. 2. patient agrees to attend follow-up assessments. 3. patients provided written informed consent for participation in the study. exclusion criteria: 1. patient participating in another interventional biologic, drug, or device clinical study that has not met its primary endpoint(s). 2. any patient considered to be part of a vulnerable population.
dydrogesterone versus gnrh antagonist in poor responders undergoing double ovarian stimulation

Conditions: Infertility

Summary: the aim of this randomized controlled trial was to compare the efficacy and cost-effectiveness of using progestin with gnrh antagonist to prevent premature lh surge in poor responders undergoing double stimulation protocol.


Eligibility criteria:
inclusion criteria: patients belonging to poseidon group 4 exclusion criteria: * pcos * endometriosis * history of recurrent abortion

Keywords: infertility ivf-et poor ovarian responders double stimulation
aiming towards evidence based interpretation of cardiac biomarkers in patients presenting with chest pain

Conditions: Acute Coronary Syndrome

Summary: the main aim of the westcor study is to * investigate the ability of two high sensitive cardiac troponin (hs-ctn) assays to diagnose acute coronary syndrome and predict prognosis in different patient populations (e.g. gender, age and co-morbidity) * to validate the suggested 1 hour protocol for rule in and rule out of acute coronary syndrome for two hs-ctn assays in an unselected chest pain population * to investigate different biomarkers ability to predict long term prognosis after hospitalization for chest pain

the westcor-study will include patients presenting to the emergency department of haukeland university hospital and stavanger university hospital with symptoms indicative of acute coronary syndrome. 1500 patients will be included at haukeland university hospital and 400 at stavanger university hospital. the two locations use different high sensitive troponin assays (i.e. hs-ctnt and hs-ctni (abbott diagnostics) for routine diagnostic of coronary syndrome. 1900 patients will be sampled and hs-ctnt or hs-ctni (as applicable) will be measured at admission, after one (2/3 of the cohort), three hours and after 8-12 hours. clinicians will be blinded to the results of the hs-ctn assay that is not used as routine assay locally. final diagnosis will be made by two independent cardiologists based on all available clinical information and results of the routine tests. the ability to diagnose or exclude mi acs, and mace at different sampling points in different patient populations will be compared for different biomarkers. 1500 patients will have a sample 1 hour after admission. the clinicians will be blinded to the results of this sample (both hs-ctn assays). the ability of the one-hour sample to diagnose or exclude myocardial infraction (mi), acs and mace will be compared between biomarkers. all patients will be invited to take a follow-up sample 3 months after discharge. the patients will further be followed for 1-5 years through national registers and the prognostic value of hs-ctn concentrations and dynamics as well as other biomarkers, will be measured.

Eligibility criteria:
inclusion criteria: * patients admitted to the emergency department with a clinical suspicion of acute coronary syndrome i.e. chest pain or pain radiating down the arms, the back, into the jaw, throat or into the lower teeth. chest pain must not be the most dominant symptom but may or may not be combined with e.g. dyspnea, nausea, anxiousness or palpitations. * age \>= 18 years exclusion criteria: * st elevation mi * age \< 18 years * patients not able to give informed consent * patients suffering from terminal illness (life expectance \< 1 month) * patients already included in the study * patients who have been stabilized at local hospitals and are referred for second opinion e.g. coronary angiography

Keywords: troponin myocardial infarction
the role of neurofilament light (nfl) in patients with hydrocephalus

Conditions: Hydrocephalus; Brain Damage; General Anesthetics Toxicity

Summary: neurofilament light chain protein (nfl) has been found by many studies as a sensitive biomarker of neuronal damage from several reasons, e.g. neurodegenerative diseases (alzheimer's disease, multiple sclerosis, etc.), inflamation (hiv) or trauma. its role as biomarker thus offers a possibility to predict and manage diseases associated with neuronal damage. therefore our aim is to investigate the changes in level of nfl in hydrocephalus and to find its role in management of treatment in hydrocephalus.


Eligibility criteria:
inclusion criteria: * in group a: * patients with diagnosed communicating hydrocephalus * mmse \> 10 points * absence of any structural laesion on mri or ct * accepted informed consent * in group b: * mmse \> 10 points * absence of any structural laesion on mri or ct * accepted informed consent * elective spinal surgery without affecting dural sac and the spinal cord * surgery shorter than 120 minutes of lasting the general anesthesia exclusion criteria: * non-communicating hydrocephalus * structural laesion on mri or ct (tumour, contusion, aneurysm) * mmse \< 10 points * life-expectancy shorter than 1 year * pre-existing other type of demetia (m. alzheimer, vascular dementia) * surgery lasting more than 120 minutes * blood loss more than 500 ml * opening of dural sac (liquororhea) * adverse events during general anestesia: map\<60 mm hg more than 5 minutes, arythmia with need for farmacological treatment

Keywords: hydrocephalus brain biomarkers neurofilament light chain general anesthesia
provincial roll-out bone health strategy

Conditions: Osteoporosis

Summary: the main purpose of this study is to investigate the effect of two different group-based exercise programs on fall risk (muscular strength and balance) and bone strength in older women aged over 65-75 years who have low bone mass. we are also trying to determine if once a week exercise is as effective on health outcomes as twice a week. we hypothesize that twice a week exercise will be more effective than once a week or sham exercise.


Eligibility criteria:
inclusion criteria: * inactive (less than twice weekly exercising) women aged 65-75 years old

Keywords: exercise resistance training
use of gallium-68 ha-dotatate pet/ct in giant cell arteritis (gca)

Conditions: Giant Cell Arteritis

Summary: the aim of this study is to compare the use of fdg pet/ct to ga-68 ha-dotatate (abbreviated dotatate) pet/ct in patients with active giant cell arteritis (gca) started on prednisone to understand if dotatate can identify more areas of active blood vessel inflammation than fdg.

the aim of this study is to prospectively evaluate the potential use of 68-ga ha-dotatate pet/ct for detecting medium-large vessel inflammation in a small number of gca patients with active disease, as compared to fdg pet/ct, and to understand if dotatate uptake correlates with disease activity. fifteen patients with active gca (either newly-diagnosed or recently relapsed disease) who are receiving glucocorticoids will be enrolled. participants will undergo baseline fdg pet/ct and baseline dotatate pet/ct scan. tracer uptake will be described in 8 major vascular territories. dotatate pet/ct will be repeated again in 6 months, and tracer uptake will be correlated to clinical disease activity, and medication use.

Eligibility criteria:
inclusion criteria: participants must: 1. meet the revised gca diagnosis criteria (modified from ref 1) 2. have either newly-diagnosed or relapsing disease 3. have active disease (modified from ref 1, to remove esr/crp requirements) 4. have been empirically started on glucocorticoid treatment (or had baseline glucocorticoid dose increased, in the case of relapsers) ≤ 2 weeks of enrolment 5. participant must be have had (or will be willing to undergo) an urgent fdg-pet/ct as part of routine clinical care. gca diagnosis criteria (modified from ref 1, to remove esr requirement). 1. age ≥ 50 years 2. and at least 1 of a. or b. : 1. unequivocal cranial symptoms of gca (new headache, scalp or temporal artery tenderness, ischemia-related vision loss, jaw/mouth claudication 2. unequivocal symptoms of polymyalgia rheumatica (pmr), defined as shoulder and/or hip girdle pain associated with inflammatory stiffness 3. and at least 1 of a. or b.: 1. temporal artery biopsy revealing features of gca 2. evidence of large-vessel vasculitis by angiography or cross-sectional imaging study such as magnetic resonance angiography (mra), computed tomography angiography (cta), or positron emission tomography-computed tomography (pet-ct) exclusion criteria: * patients not meeting the above criteria or who are unable to provide informed consent will be excluded.
parental involvement improves the effect of motivational interviewing on weight loss in obese adolescents: a randomized controlled trial study

Conditions: Obesity, Adolescent

Summary: motivational interviewing (mi) has been shown to be an effective strategy in targeting obesity in adolescents and parental involvement has been associated with increased effectiveness. the aim of the study is to evaluate and compare the role of parental involvement in mi interventions for obese adolescents


Eligibility criteria:
inclusion criteria: * bmi equal or higher than 95th percentile for age and gender * 13-18 years old exclusion criteria: * medication with weight gain as side effects * diagnosed with having eating disorder * pregnant * clinical mental health conditions * psychosis

Keywords: obese adolescents bmi ≥ 95th percentile for age and gender
neuropathic in the acute post operative phase

Conditions: Lung Cancer

Summary: investigation of thermal thresholds and sensory mapping to thermal stimuli


Eligibility criteria:
inclusion criteria: * age \> 18 years old exclusion criteria: * do not under stand danish * cognitive reduction * previous thoracic surgery * pregnant or nursing * inability to cooperate to pain scoring
cancer and osteoporosis research with alendronate and lupron (c.o.r.a.l )

Conditions: Osteoporosis

Summary: multi-center,double blind randomized phase iii placebo controlled study in 250 men with histologically proven prostate cancer with out bone metastases who are beginning adt therapy and who will receive concomitant treatment with either oral fosamax 70mg once weekly or placebo for one year.these men will be treated and follow up for one year,during which time changes in bmd, markers of bone resorption and formation will be monitored.all patients will receive calcium and vitamin d through out the study.

this is a phase three multicentre, double blind, randomize parallel group, placebo-controlled study in 250 men with histologically proven cancer without bone metastases who are beginning adt therapy and who will receive a concomitant treatment with either oral fosamax 70 mg once a weak (n=125) or placebo (n=125) for one year. changes in bmd, markers of bone absorption and formation are monitored.

Eligibility criteria:
inclusion criteria: * histologically/cytologically proven, non-metastatic (m0) adenocarcinoma of the prostate. * life expectancy of \> 12 months. * initiation of treatment with the luteinizing hormone-releasing hormone agonist (lhrh-a) lupron no more than 15 days prior or 30 days following, baseline visit. * requiring treatment with lhrh agonists for prostate cancer, for a duration of at least 12 months from baseline. * eastern cooperative oncology group (ecog) performance status 0, 1 or 2 * prior to any study-specific procedures, subject (and/or their legally authorized representative) has voluntarily signed and dated an informed consent form. exclusion criteria: bone metastases current or previous use with in past 12 months of bisphosphonate. known hypersensitivity to lhrh. hypocalcaemia. severe renal impairment, abnormal liver function, hypothyroidism, hyperthyroidism, bilateral hip replacement. use of lhrh or anti-androgen medication within last 12 months. abnormalities of esophagus which delay esophageal emptying. inability to stand or sit upright for at least 30 minutes.
safety and immunogenicity evaluation after one or two doses of novartis meningococcal acwy conjugate vaccine in healthy infants and toddlers

Conditions: Meningococcal Meningitis

Summary: the primary immunogenicity objective is to assess and compare the immunogenicity of one dose of menacwy to one dose of menjugate given to healthy toddlers at 12 months of age as measured by the percentage of subjects with serum bactericidal titers directed against n. meningitidis serogroup c ≥ 1:8 obtained in the serum bactericidal assay using human complement (hsba).


Eligibility criteria:
inclusion criteria: * infants 6 to 8 months old inclusive, who were born after full term pregnancy and previously received three doses of both prevenar and infanrix-hexa vaccines at least 30 days before study entry exclusion criteria: * who previously received any meningococcal vaccine; * who have had a previous confirmed or suspected disease caused by n. meningitidis, c. diphtheriae, c. tetani, poliovirus, hepatitis b, hib, pneumococcus or b. pertussis; * who have had household contact with and/or intimate exposure to an individual with laboratory confirmed n. meningitidis (serogroups a, c, w135, or y), b. pertussis, hib, c. diphtheriae, polio, or pneumococcal infection at any time since birth; * subjects with any serious, acute or chronic progressive disease

Keywords: meningococcal acwy conjugate vaccine meningitis toddlers infants concomitant vaccination